Related Experiment Video
Updated: Sep 2, 2025
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Lipid Lowering Therapy: An Era Beyond Statins
Toufik Abdul-Rahman1, Syed Muhammad Awais Bukhari2, Emiliano Cantu Herrera3
1Sumy State University, Toufik's World Medical Association, Sumy, Sumy Oblast, Ukraine.
Insights
Non-statin therapies offer new options for managing dyslipidemia and lowering low-density lipoprotein (LDL) cholesterol. Bempedoic acid, a statin-like drug, effectively reduces cholesterol without causing myopathy, expanding treatment choices beyond traditional statins.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Genetics
Background:
- Dyslipidemia, characterized by elevated low-density lipoprotein (LDL) cholesterol, is a major risk factor for atherosclerotic cardiovascular disease (ASCVD), myocardial infarction, and stroke.
- Statins, inhibitors of HMG-CoA reductase, are the primary treatment for cardiovascular disease prevention and lipid reduction but can cause side effects like myopathy.
- The need for alternative and adjunct therapies has driven the development of numerous non-statin lipid-lowering treatments.
Purpose of the Study:
- To review current and emerging non-statin lipid-lowering therapies.
- To examine recent advances in gene-based therapies for dyslipidemia.
- To compare the mechanisms and side effect profiles of various lipid-lowering agents.
Main Methods:
- Literature review of non-statin lipid-lowering drugs and gene-based therapies.
- Analysis of therapeutic mechanisms, efficacy, and side effect profiles.
- Comparison of Bempedoic acid with statins regarding cholesterol reduction and myopathy risk.
Main Results:
- Several non-statin classes exist, including Bile acid sequestrants, Fibrates, Nicotinic acid, Ezetimibe, Bempedoic acid, Volanesoren, Evinacumab, and PCSK9 Inhibitors (Evolocumab, Alirocumab).
- Emerging gene-based therapies include Small interfering RNAs, Antisense oligonucleotides, Adeno-associated virus vectors, CRISPR/Cas9, and Non-coding RNA therapies.
- Bempedoic acid effectively lowers cholesterol via a pathway similar to statins but without associated myopathy.
Conclusions:
- While statins remain the standard of care, non-statin therapies are crucial for managing dyslipidemia, especially for patients intolerant to statins.
- The expanding array of lipid-lowering options, including novel gene-based approaches, provides personalized treatment strategies.
- Bempedoic acid represents a significant advancement, offering a statin-like benefit without the common side effect of myopathy.
Abstract:
Dyslipidemia, specifically elevated low-density lipoprotein (LDL) cholesterol levels, causes atherosclerotic cardiovascular disease (ASCVD) and increases the risk of myocardial infarction and stroke. Statins, a class of drugs that exert their effects by inhibiting HMG-CoA reductase, a key enzyme in the synthesis of cholesterol, have been the mainstay of therapy for the primary prevention of cardiovascular disease and lipids reduction. Statins are associated with side effects, most commonly myopathy and myalgias, despite their proven efficacy. This review explores non-statin lipid-lowering therapies and examines recent advances and emerging research. Over the previous decades, several lipid-lowering therapies, both as monotherapy and adjuncts to statin therapy and lipid-targeting gene therapy, have emerged, thus redefining how we treat dyslipidemia. These drugs include Bile acids sequestrants, Fibrates, Nicotinic acid, Ezetimibe, Bempedoic acid, Volanesoren, Evinacumab, and the PCSK 9 Inhibitors Evolocumab and Alirocumab. Emerging gene-based therapy includes Small interfering RNAs, Antisense oligonucleotides, Adeno-associated virus vectors, CRISPR/Cas9 based therapeutics, and Non-coding RNA therapy. Of all these therapies, Bempedoic acid works most like statins by working through a similar pathway to decrease cholesterol levels. However, it is not associated with myopathy. Overall, although statins continue to be the gold standard, non-statin therapies are set to play an increasingly important role in managing dyslipidemia.
More Related Videos
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:26Atherosclerosis III: Management
01:25Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
01:18Lipids: Dietary Sources and Requirements
01:24Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...